Literature DB >> 16533769

The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model.

Charbel Bouez1, Caroline Reynaud, Emmanuelle Noblesse, Amélie Thépot, Claudine Gleyzal, Jean Kanitakis, Eric Perrier, Odile Damour, Pascal Sommer.   

Abstract

Lysyl oxidase initiates the enzymatic stage of collagen and elastin cross-linking. Among five isoforms comprising the lysyl oxidase family, LOX is the better studied. LOX is associated to an antitumor activity in ras-transformed fibroblasts, and its expression is down-regulated in many carcinomas. The aim of this work was to shed light on LOX functions within the epidermis by studying its expression in human basal and squamous cell carcinomas and analyzing the effect of its enzymatic activity inhibition and protein absence on human keratinocytes behavior in a skin equivalent. In both carcinomas, LOX expression by epidermal tumor cells was lacking, while it was up-regulated around invading tumor cells in association with the stromal reaction. Lysyl oxidase activity inhibition using beta-aminoproprionitrile in a skin equivalent model prepared with both primary human keratinocytes and HaCaT cell line affected keratin 10 and filaggrin expression and disorganized the collagen network and the basement membrane. In spite of all these changes, no invasion phenotype was observed. Modelization of the invasive phenotype was only noticed in the skin equivalent developed with LOX antisense HaCaT cell line, where the protein LOX is specifically absent. Our results clearly indicate that lysyl oxidase enzymatic activity is essential not only for the integrity maintenance of the dermis but also for the homeostasis of the epidermis. Moreover, LOX protein plays a role in the skin carcinomas and invasion but not through its enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533769     DOI: 10.1158/1078-0432.CCR-05-1456

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

Review 1.  Human copper-dependent amine oxidases.

Authors:  Joel Finney; Hee-Jung Moon; Trey Ronnebaum; Mason Lantz; Minae Mure
Journal:  Arch Biochem Biophys       Date:  2014-01-06       Impact factor: 4.013

2.  Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.

Authors:  Juan Liu; Wei Ping; Yukun Zu; Wei Sun
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells.

Authors:  Seiichi Sato; Philip C Trackman; Joni M Mäki; Johanna Myllyharju; Kathrin H Kirsch; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

4.  The lysyl oxidase propeptide interacts with the receptor-type protein tyrosine phosphatase kappa and inhibits β-catenin transcriptional activity in lung cancer cells.

Authors:  Nuria Sánchez-Morgan; Kathrin H Kirsch; Philip C Trackman; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2011-06-20       Impact factor: 4.272

Review 5.  Lysyl oxidase: a potential target for cancer therapy.

Authors:  V M Berlin Grace; C Guruvayoorappan
Journal:  Inflammopharmacology       Date:  2010-11-24       Impact factor: 4.473

6.  Lysyl oxidase, extracellular matrix remodeling and cancer metastasis.

Authors:  Qian Xiao; Gaoxiang Ge
Journal:  Cancer Microenviron       Date:  2012-04-13

7.  Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells.

Authors:  Héctor A Lucero; Katya Ravid; Jessica L Grimsby; Celeste B Rich; Sandra J DiCamillo; Joni M Mäki; Johanna Myllyharju; Herbert M Kagan
Journal:  J Biol Chem       Date:  2008-06-27       Impact factor: 5.157

8.  A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer.

Authors:  Chengyin Min; Ziyang Yu; Kathrin H Kirsch; Yingshe Zhao; Siddharth R Vora; Philip C Trackman; Douglas B Spicer; Lynn Rosenberg; Julie R Palmer; Gail E Sonenshein
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

Review 9.  The rationale for targeting the LOX family in cancer.

Authors:  Holly E Barker; Thomas R Cox; Janine T Erler
Journal:  Nat Rev Cancer       Date:  2012-07-19       Impact factor: 60.716

10.  A dialogue between the hypoxia-inducible factor and the tumor microenvironment.

Authors:  Frédéric Dayan; Nathalie M Mazure; M Christiane Brahimi-Horn; Jacques Pouysségur
Journal:  Cancer Microenviron       Date:  2008-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.